Regulatory
Novartis’ Kesimpta Notches FDA Approval as Targeted B-cell Therapy for Patients with Relapsing MS
2020-08-23
Seres Therapeutics’ Microbiome Therapy for Recurrent C. difficile Infections, Shines in Phase 3
2020-08-12
Part I Highlights of BIO Asia-Taiwan 2020 (Day 1): The Effect of COVID-19 on Global Biotech Industry
2020-07-22Partner